SCHEDULE: Vanguard Group Reports 0% Stake in Abbott Labs

The Vanguard Group has amended its Schedule 13G filing for Abbott Laboratories, reporting 0% beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 12 to Schedule 13G for Abbott Laboratories' Common Stock.
• The filing reports 0% beneficial ownership of Abbott Laboratories' Common Stock by The Vanguard Group.
• This change is attributed to an internal realignment at The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative update for Abbott Laboratories, reflecting an internal reporting change by The Vanguard Group rather than a divestment of underlying assets from Vanguard's broader managed funds.

Negatives

• The Vanguard Group, as the reporting entity, no longer directly reports beneficial ownership of Abbott Laboratories' common stock, moving to 0%.

Future Outlook

No forward-looking statements or guidance regarding Abbott Laboratories' performance or The Vanguard Group's future investment strategy are provided in this administrative filing.

Industry Context

StockSavvy.ai notes that large institutional investors like The Vanguard Group frequently undergo internal restructurings or reallocations of reporting responsibilities, which can lead to amendments in their Schedule 13G filings. This particular filing reflects an administrative change in how Vanguard reports its beneficial ownership rather than a strategic shift in its overall investment in Abbott Laboratories.

Stakeholder Impact

• Shareholders of Abbott Laboratories: Minimal direct impact, as the underlying shares are likely still held within Vanguard's broader managed funds, just reported differently by separate entities.
• The Vanguard Group: Significant internal reporting change, disaggregating beneficial ownership reporting from the parent entity to its subsidiaries/business divisions.

Key Dates

Recommendation

The filing primarily reflects an administrative change in how The Vanguard Group reports its beneficial ownership due to an internal realignment. It does not indicate a fundamental change in Abbott Laboratories' prospects or The Vanguard Group's overall investment strategy regarding the company's underlying assets. Therefore, a 'hold' recommendation is appropriate as this filing provides no new information to alter an investment thesis.

Keywords

Abbott Laboratories, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Institutional Investor, Internal Realignment, Common Stock, Investment Management